2×more weight lost vs semaglutide SURMOUNT-5 head-to-head
Source: Jastreboff AM et al. N Engl J Med. 2022;387:205-216. Results with diet + exercise + once-weekly tirzepatide 15mg. Individual results vary.
FDA-Approved
Dual GIP + GLP-1
VitaCure RX · licensed US pharmacies
Zepbound at a glance
Only FDA-approved dual GIP/GLP-1 for chronic weight management.
Avg 22.5% body weight lost at 15mg (SURMOUNT-1, 72 weeks, with diet + exercise).
63% of patients lost ≥20% body weight at the 15mg dose.
Once-weekly subcutaneous injection — same day each week.
Available in 6 dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.
Requires BMI ≥30 or BMI ≥27 with ≥1 weight-related condition.
Dual GIP/GLP-1 Weight Loss Injection
Buy Zepbound® Online
Tirzepatide · Dual GIP/GLP-1 · Via VitaCure RX by Vitercure
Avg 22.5% body weight lost — SURMOUNT-1 trial at 15mg with diet + exercise
Zepbound® (tirzepatide) is an FDA-approved, once-weekly dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related medical condition, used with a reduced-calorie diet and increased physical activity. Through Vitercure's HIPAA-secure VitaCure RX telehealth
platform, eligible adults can complete a brief online intake, meet with a licensed clinician, and if
appropriate, receive a Zepbound prescription dispensed by licensed US partner pharmacies with
cold-chain, temperature-controlled shipping — no lengthy in-person visit required.
The most effective FDA-approved weight-loss injection — online access
Answer a short questionnaire. A licensed clinician reviews your health history and may prescribe Zepbound.
No surprise subscriptions — clear, one-time pack pricing.
Individual results vary. Always speak with your clinician about your own expectations.
RK
"I lost 47 lbs in 7 months on Zepbound at 10mg. What surprised me most was how my appetite just completely changed — I stopped thinking about food constantly."
47 lbs · 7 months · 10mg
TM
"After trying Wegovy and not getting much response, my doctor switched me to Zepbound. The difference was noticeable within weeks. Down 38 lbs in 6 months."
38 lbs · 6 months · 12.5mg
JC
"I was skeptical, but the results were real. My A1C also came down from 7.8 to 5.9 as a bonus. Lost 31 lbs in 5 months at the 7.5mg dose."
31 lbs · 5 months · 7.5mg
What is Zepbound® (Tirzepatide)?
Zepbound (tirzepatide) is an FDA-approved prescription weight-loss injection developed by Eli Lilly.
It is the first and only approved dual GIP and GLP-1 receptor agonist specifically indicated for chronic
weight management. By activating both the glucose-dependent insulinotropic polypeptide (GIP) receptor
and the glucagon-like peptide-1 (GLP-1) receptor simultaneously, Zepbound targets appetite and
metabolism through two distinct hormonal pathways — unlike semaglutide-based medications (Wegovy,
Ozempic), which act on GLP-1 alone.
How Zepbound's dual mechanism works
GIP receptor activation
GIP acts on fat cells and the brain to reduce appetite, improve fat metabolism and may enhance the GLP-1 effect. Some researchers believe GIP activation is key to why tirzepatide outperforms GLP-1-only medications in head-to-head trials.
GLP-1 receptor activation
GLP-1 signals fullness to the brain, slows gastric emptying so you feel satisfied longer, reduces appetite and helps regulate post-meal blood sugar — well-established benefits from medications like Wegovy and Ozempic.
Who qualifies for Zepbound?
Zepbound is indicated for adults with a BMI of 30 kg/m² or higher, or those with a BMI of 27 kg/m²
or higher who have at least one weight-related medical condition such as high blood pressure, type 2
diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease. A licensed Vitercure
clinician will review your full medical history before any prescription is issued.
Zepbound vs Mounjaro — same drug, different approvals
Both Zepbound and Mounjaro®
contain tirzepatide. Mounjaro is approved for glycemic control in adults with type 2 diabetes, while
Zepbound is approved for chronic weight management — the key difference is the FDA indication, not the
active ingredient. The dosing schedules are similar but may differ; your clinician will determine the
most appropriate branded product and dose based on your goals and insurance situation.
Zepbound Weight Loss Results — SURMOUNT Trial Data
Zepbound's pivotal trial program — SURMOUNT — is the largest and most rigorous tirzepatide weight-loss
trial dataset, enrolling thousands of adults with obesity or overweight across multiple studies.
SURMOUNT-1 — Primary Pivotal Trial
N=2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) + ≥1 weight-related condition (excluding
type 2 diabetes). 72 weeks on once-weekly tirzepatide + diet + exercise vs placebo.
22.5%
Avg body weight lost at 15mg (vs 2.4% placebo)
20.9%
Avg body weight lost at 10mg
16.0%
Avg body weight lost at 5mg
Source: Jastreboff AM et al. N Engl J Med. 2022;387:205-216.
SURMOUNT-1 outcomes by dose
Zepbound SURMOUNT-1 weight loss outcomes by dose at 72 weeks
Weekly dose
Avg weight loss
% losing ≥5%
% losing ≥15%
% losing ≥20%
Placebo
2.4%
35%
9%
5%
5mg
16.0%
85%
49%
30%
10mg
20.9%
89%
67%
51%
15mg (max)
22.5%
96%
77%
63%
All outcomes at 72 weeks with diet + exercise. Source: SURMOUNT-1, N Engl J Med. 2022.
Zepbound weight loss timeline — what to expect month by month
Timeframe
Typical experience
Weeks 1–4 (2.5mg)
Appetite and cravings begin to shift. GI adjustment common. Expect 1–4 lbs loss.
Month 2 (5mg)
Weight loss accelerates. Many patients report 1–2% body weight/month at therapeutic dose.
Months 3–5
Continued titration (7.5–10mg). Noticeable body composition changes. Higher energy.
Months 6–12+
SURMOUNT-1 avg 22.5% total body weight lost at 15mg by 72 weeks. Most significant results in second half of treatment.
SURMOUNT-5 — Tirzepatide vs Semaglutide (Wegovy) Head-to-Head
In the first head-to-head trial comparing tirzepatide (Zepbound) directly against semaglutide 2.4mg
(Wegovy), tirzepatide patients lost approximately twice as much body weight — making it the most
effective FDA-approved weight-loss injection currently available.
~20%
Tirzepatide (Zepbound)
~13%
Semaglutide 2.4mg (Wegovy)
SURMOUNT-5 results; patients with obesity or overweight without diabetes. ~72 weeks. Results may vary.
How Zepbound® Works & Typical Dosing
Administration basics
Form: Pre-filled multi-dose pen (4 weekly doses per pen).
Route: Subcutaneous injection (under the skin).
Frequency: Once weekly, same day each week.
Sites: Abdomen, thigh, or upper arm. Rotate injection sites.
Initiation — helps body adjust. GI effects typically peak here.
Weeks 5–8
5mg
First therapeutic step-up if tolerated.
Weeks 9–16
7.5mg
Mid-range. SURMOUNT-1 showed meaningful weight loss at this dose.
Weeks 17–24
10mg
20.9% avg body weight loss at 72 wks (SURMOUNT-1).
Weeks 25–32
12.5mg
Higher-dose option for appropriate patients.
Week 33+
15mg
Maximum dose. 22.5% avg body weight loss at 72 wks (SURMOUNT-1).
This is a general reference, not a personal prescription. Your clinician determines your dose.
Clinician insight: Zepbound works best as part of a comprehensive program — not just a medication. Vitercure patients get access to nutrition guidance, movement resources, and behavioral support to maximize and maintain their results.
Zepbound® vs Wegovy vs Ozempic — How Do They Compare?
The most common comparison queries for Zepbound center on how it stacks up against Wegovy
(semaglutide 2.4mg) and Ozempic (semaglutide 2mg). Here is a direct clinical comparison.
Comparison of Zepbound vs Wegovy vs Ozempic for weight loss
Feature
Zepbound® (tirzepatide)
Wegovy® (semaglutide)
Ozempic® (semaglutide)
Mechanism
Dual GIP + GLP-1
GLP-1 only
GLP-1 only
FDA weight loss approval
Yes — Zepbound (2023)
Yes — Wegovy (2021)
No (off-label)
Avg weight loss (pivotal)
22.5% body weight (15mg, SURMOUNT-1)
15.3% body weight (STEP-1)
~6–9% (SUSTAIN-1)
Head-to-head vs Wegovy
~2× more weight lost (SURMOUNT-5)
Reference arm
Not compared directly
% losing ≥20% weight
63% at 15mg
~30% at 2.4mg
Not indicated for weight loss
Max approved dose
15mg/week
2.4mg/week
2mg/week (diabetes)
Dosing schedule
Once weekly
Once weekly
Once weekly
CV outcomes trial
SURMOUNT-MMO (ongoing)
SELECT (20% MACE reduction)
SUSTAIN-6 (26% MACE reduction)
Clinical comparisons are for educational purposes only. Only a licensed clinician can determine the most appropriate treatment for you.
Zepbound vs Mounjaro — what's the difference?
Both contain tirzepatide — the same active ingredient. Zepbound is FDA-approved for
chronic weight management. Mounjaro®
is FDA-approved for glycemic control in type 2 diabetes. Some patients with diabetes receive Mounjaro,
which may also produce significant weight loss. Your prescriber determines which is appropriate based
on your diagnosis, insurance, and goals.
Zepbound® Cost & Access — VitaCure RX by Vitercure
Zepbound pricing varies by dose strength, number of pens, and source pharmacy. VitaCure RX by Vitercure
offers transparent, one-time pack pricing with no surprise automatic subscriptions.
What your cost may include
Telehealth intake + clinician evaluation
Zepbound prescription if clinically appropriate
Dispensed by licensed US partner pharmacies
Cold-chain temperature-controlled shipping
Access to Vitercure weight-loss education library
Insurance & payment
VitaCure RX primarily operates as a cash-pay service. Insurance coverage for GLP-1 and dual GIP/GLP-1 medications varies widely. You may be able to use HSA or FSA funds — confirm with your benefits provider.
Zepbound cost without insurance: Eli Lilly's list price is approximately $1,060/month for the branded product through retail pharmacies. VitaCure RX pricing through partner pharmacies is displayed in the pack selectors above.
Eli Lilly savings programs: Eligible commercially insured patients may qualify for Lilly's savings program directly. Ask your clinician or visit lilly.com for current program details. VitaCure RX cannot guarantee eligibility for manufacturer programs.
Important Safety Information — Zepbound®
This is not a complete list of all warnings, side effects, or contraindications. Always review the full Prescribing Information and Medication Guide, and speak with a licensed clinician.
Boxed warning: thyroid C-cell tumors
Do not use Zepbound if you or a family member have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contact your clinician if you notice a neck lump, trouble swallowing, hoarseness, or shortness of breath.
Other serious risks
Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially when combined with diabetes medications), kidney injury, severe GI issues, and serious allergic reactions. Seek urgent care for severe abdominal pain, signs of allergic reaction, or any symptom that concerns you.
Common side effects
The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort — most prominent during dose escalation and often lessening as the body adjusts. Slow, gradual titration as supervised by your clinician is the primary strategy for minimizing GI effects.
Zepbound and muscle loss
Rapid weight loss with any medication can include muscle mass loss, not only fat. Vitercure clinicians and our education library emphasize adequate protein intake and resistance exercise during Zepbound treatment to help preserve lean muscle mass.
Zepbound® FAQ
In the SURMOUNT-1 phase 3 trial (N=2,539, 72 weeks), adults using tirzepatide 15mg alongside diet and exercise lost an average of 22.5% of body weight — compared to 2.4% on placebo. At 10mg, the average was 20.9%; at 5mg, 16.0%. 63% of patients on 15mg achieved ≥20% body weight loss. Individual results vary significantly based on dose, adherence, diet, exercise, and other health factors.
Head-to-head data from SURMOUNT-5 showed that tirzepatide (Zepbound) produced approximately twice as much weight loss as semaglutide 2.4mg (Wegovy) in patients with obesity or overweight without type 2 diabetes. Zepbound's dual GIP/GLP-1 mechanism may account for this difference. However, the "better" choice depends on individual factors — your clinician will evaluate your medical history, tolerability profile, and goals before recommending a specific medication.
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a BMI ≥30 kg/m², or a BMI ≥27 kg/m² with at least one weight-related medical condition (such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea). It is used alongside a reduced-calorie diet and increased physical activity.
Both Zepbound and Mounjaro contain tirzepatide — the same active ingredient. Zepbound is FDA-approved specifically for chronic weight management; Mounjaro is approved for glycemic control in type 2 diabetes. The dosing schedules are similar. Your prescriber determines which is appropriate based on your diagnosis, goals, and insurance.
Yes. Through Vitercure's HIPAA-secure VitaCure RX telehealth platform, eligible adults can complete a brief online intake, meet with a licensed clinician, and — if appropriate — receive a Zepbound prescription fulfilled by licensed US partner pharmacies with cold-chain, temperature-controlled shipping. A valid prescription is required; Zepbound cannot be legally dispensed without one.
Polycystic ovary syndrome (PCOS) is associated with insulin resistance, elevated androgens, and obesity — all areas where tirzepatide's dual GIP/GLP-1 mechanism may be beneficial. While Zepbound is not specifically FDA-approved for PCOS, growing clinical evidence and ongoing research suggest it may help patients with PCOS-related insulin resistance and weight challenges. Your Vitercure clinician will assess whether Zepbound is appropriate for your specific situation.
Zepbound is a medication for chronic weight management, not a short-term treatment. SURMOUNT-1 data at 72 weeks showed continued benefits; stopping leads to weight regain in most patients. Many people remain on Zepbound long-term as part of ongoing metabolic care. Your Vitercure care team will periodically reassess your progress, tolerability, and goals.
The SURMOUNT-4 trial demonstrated that discontinuing tirzepatide after 36 weeks leads to gradual weight regain — participants who switched to placebo regained most of the weight lost within about a year. Appetite and food cravings typically return. Never stop Zepbound without speaking to your clinician, who can help plan a transition, dose adjustment, or alternative strategy.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort — typically most pronounced during dose escalation. Serious but rare risks include pancreatitis, gallbladder problems, kidney injury, low blood sugar (with diabetes medications), and allergic reactions. Zepbound carries a boxed warning for possible thyroid C-cell tumors; it is contraindicated in patients with a personal or family history of MTC or MEN 2.
Zepbound vs Wegovy — The Most Important Comparison in Weight Loss Medicine
The SURMOUNT-5 trial changed the conversation about weight-loss medications by directly comparing
tirzepatide (Zepbound) against semaglutide 2.4mg (Wegovy) for the first time. Patients randomized to
tirzepatide lost approximately twice as much body weight as those on semaglutide — making Zepbound the
highest-efficacy FDA-approved weight-loss medication currently available. The dual GIP/GLP-1 mechanism
is widely believed to be responsible for this advantage: activating two distinct hormonal receptors
appears to produce greater appetite suppression and metabolic benefits than targeting GLP-1 alone.
That said, Wegovy is not without advantages. It has an established long-term safety profile with extensive
real-world data, and the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events
in patients with pre-existing cardiovascular disease — data that Zepbound's cardiovascular outcomes trial
(SURMOUNT-MMO) is still accumulating. Your Vitercure clinician will weigh both options against your complete
health profile.
How Much Weight Can You Actually Lose on Zepbound?
The most searched question about Zepbound is how much weight it actually produces — and the SURMOUNT-1
trial data gives the clearest answer yet. At the maximum 15mg dose over 72 weeks, patients lost an average
of 22.5% of their body weight — equivalent to approximately 51 lbs for someone weighing 225 lbs.
63% of patients at 15mg lost 20% or more of their body weight, and 96% lost at least 5%. These are
outcomes that far exceed any previous FDA-approved weight-loss medication.
Practically, weight loss on Zepbound is not linear. The first month at 2.5mg is an adjustment period;
most patients lose 1–4 lbs. As the dose escalates — typically reaching the therapeutic range between
months 2 and 6 — weight loss accelerates. The most significant results in SURMOUNT-1 came in the second
half of the 72-week study. Consistent adherence to dosing, combined with dietary changes, physical activity,
and regular clinician follow-up, determines whether patients reach the trial's headline outcomes.
Zepbound for PCOS and Insulin Resistance
Although Zepbound is not specifically approved for polycystic ovary syndrome (PCOS), the mechanism of
action is directly relevant. PCOS is fundamentally linked to insulin resistance, hyperinsulinemia, and
excess body weight — all areas where tirzepatide's dual GIP/GLP-1 pathway has demonstrated measurable
effects. Reducing insulin levels through improved insulin sensitivity can lower androgen production,
which in turn may improve menstrual regularity, reduce hirsutism, and support ovulation in some women.
A growing body of case reports and retrospective studies — as well as several ongoing trials — is evaluating
tirzepatide specifically in PCOS populations. If PCOS is your primary concern, your Vitercure clinician
will assess whether Zepbound, metformin, or a combination is the most appropriate approach for your goals
and overall health profile.
“
Clinician perspective on Zepbound
Zepbound represents a genuine step change in what's pharmacologically achievable for obesity treatment.
The SURMOUNT-5 data showing roughly twice the weight loss versus Wegovy has shifted how I approach
conversations with patients. The dual mechanism — GIP plus GLP-1 — appears to target appetite centers
more comprehensively than GLP-1 alone. I still prioritize lifestyle support alongside the medication:
patients who pair Zepbound with real dietary and activity changes tend to maintain their results better
long-term.
This perspective is general and does not constitute personal medical advice. A Vitercure clinician will review your full health profile before any treatment is recommended.
More than a prescription — the Vitercure weight-loss library
Medications like Zepbound are most effective when paired with structured lifestyle support.
Vitercure gives you access to an evidence-based education library covering nutrition, movement,
sleep, mindset, and long-term weight maintenance designed around GLP-1 and dual-agonist therapy.
Understand exactly how Zepbound works and what to expect each month.
Nutrition frameworks for GLP-1 users
Meal planning that maximizes results and supports lean muscle preservation.
Progress tracking tools
Monitor weight trends, side effects, and prepare for clinician check-ins.
Medically Reviewed
Dr. Jane Rote, MD
Board-Certified in Endocrinology & Metabolism
Last medical review: November 2025
Content reviewed for clinical accuracy
Start your Zepbound® journey with VitaCure RX
Answer a brief questionnaire. A licensed Vitercure clinician reviews your history and may prescribe
Zepbound — dispensed by licensed US pharmacies with cold-chain shipping. No lengthy in-person visit required.
